OTCPK:HXBM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Helix BioMedix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HXBM's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

HXBM

0.2%

US Biotechs

2.8%

US Market


1 Year Return

n/a

HXBM

25.7%

US Biotechs

9.3%

US Market

Return vs Industry: Insufficient data to determine how HXBM performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how HXBM performed against the US Market.


Shareholder returns

HXBMIndustryMarket
7 Day0%0.2%2.8%
30 Day-37.0%9.1%8.9%
90 Dayn/a11.9%-0.5%
1 Yearn/a26.9%25.7%11.8%9.3%
3 Year-46.7%-46.7%34.8%30.3%31.4%22.7%
5 Year-45.5%-45.5%-2.5%-8.3%58.7%40.9%

Price Volatility Vs. Market

How volatile is Helix BioMedix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Helix BioMedix undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Helix BioMedix is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Helix BioMedix has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of HXBM’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Helix BioMedix regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Helix BioMedix forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

30.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Helix BioMedix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Helix BioMedix performed over the past 5 years?

22.7%

Historical Pharmaceuticals & Biotech annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Helix BioMedix has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Helix BioMedix's financial position?


In this section we usually analyse Helix BioMedix's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Helix BioMedix has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of HXBM’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Helix BioMedix's financial data was last updated here.
  • Explore more healthy companies in the Pharmaceuticals & Biotech industry.

Dividend

What is Helix BioMedix's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HXBM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HXBM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HXBM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HXBM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HXBM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average board tenure


CEO

Robin Carmichael (62yo)

2.92yrs

Tenure

US$304,350

Compensation

Ms. Robin L. Carmichael has been the Chief Executive Officer of Helix Biomedix Inc. since July 10, 2017 and its President since February 2015 and served as its Chief Operating Officer since January 12, 201 ...


Board Members

NamePositionTenureCompensationOwnership
Robin Carmichael
President2.92yrsUS$304.35kno data
John Clifford
Director12.83yrsUS$21.80kno data
R. Beatty
Chairman of the Board5.33yrsUS$414.35kno data
Richard Cohen
Director14.5yrsUS$23.60kno data
William Goolsbee
Director0.67yrno datano data
Zoe Draelos
Member of Scientific Advisory Boardno datano datano data
Lawrence Jones
Director10.25yrsUS$21.30kno data
Stephen Lloyd
Member of Scientific Advisory Board0.42yrno datano data
Amanda McCullough
Member of Scientific Advisory Board0.42yrno datano data

5.3yrs

Average Tenure

68yo

Average Age

Experienced Board: HXBM's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Helix BioMedix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Helix BioMedix, Inc.
  • Ticker: HXBM
  • Exchange: OTCPK
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$5.175m
  • Shares outstanding: 205.37k
  • Website: https://www.helixbiomedix.com

Location

  • Helix BioMedix, Inc.
  • 22121-17th Avenue SE
  • Suite 112
  • Bothell
  • Washington
  • 98021
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HXBMOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJul 1995

Biography

Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/01 02:42
End of Day Share Price2020/05/20 00:00
Earnings2012/09/30
Annual Earnings2011/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.